NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Olatec Therapeutics

Olatec Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.olatec.com/

Last Round

Series B

Nov 9, 2025

Total Funding Raised

$40M

Company Overview

Olatec Therapeutics is a biopharmaceutical company that develops oral small-molecule therapeutics targeting the NLRP3 inflammasome and Interleukin-1 pathways to treat inflammatory and immune-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

NLRP3 inflammasome inhibitordapansutrilesmall-molecule therapeuticsclinical-stage biotechanti-inflammatory druginnate immune responsedrug developmentclinical trialsbiopharmaOLT1177immuno-endocrinologyoral therapychronic inflammationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Olatec Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Olatec Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Olatec Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 9, 2025
GrantFeb 20, 2024
GrantMar 10, 2023
Series AFeb 23, 2023

Key People

Founding team and executive leadership

Damaris Skouras

Founder CEO

Founding Team

Olatec Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 2, 2025

    Andy Cunningham joins the Board of Directors.

  • Jan 28, 2025

    Marc Y. Donath joins the Clinical Advisory Board.

Olatec Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Olatec Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Olatec Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range14
Year Founded2003
Last FundingNov 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.